Rotterdam, April 1, 2008 – the Erasmus MC Biomedical Fund is pleased to announce the successful spin-out and financing of a new biotech company, Therosteon B.V. Therosteon is a spin-off company from the Erasmus University Medical Center in Rotterdam. Its goal is to further develop novel therapies for bone diseases. Therosteon’s technology is based on a proprietary drug development platform, which enables the company to generate new drug targets and therapies for a variety of bone diseases, including osteoporosis and bone metastasis. Therosteon’s scientific founder is Hans van Leeuwen, Professor at the Department of Internal Medicine of the Erasmus MC and expert in the field of bone diseases and vitamin D biology.
